Astrica

Astria Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and orphan diseases, with a primary emphasis on hereditary angioedema (HAE). The company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein designed to provide long-acting prophylaxis for HAE with infrequent dosing. Astria is also expanding its pipeline into other allergic and immunological diseases, such as atopic dermatitis, through its STAR-0310 program targeting OX40. Formerly known as Catabasis Pharmaceuticals, the company rebranded to Astria following the acquisition of Quellis Biosciences and a strategic shift toward rare disease treatments.